Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CYB 003

Next Previous
X
Search
Drug Profile

CYB 003

Alternative Names: CYB-003

Latest Information Update: 04 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cybin
  • Class Antidepressants; Antipsychotics; Behavioural disorder therapies; Drug withdrawal therapies; Tryptamines
  • Mechanism of Action Serotonin 5-HT2A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Major depressive disorder
  • Preclinical Alcoholism; Psychiatric disorders

Most Recent Events

  • 20 Sep 2024 Cybin plans phase-III EXTEND trial for Major depressive disorder in February 2025 (PO), (NCT06605105),
  • 13 Aug 2024 Cybin plans to initiate a CYB003-002 phase III pivotal trial for Major Depressive Disorder (Adjunctive treatment) in the USA and EU in November 2024 (PO) (NCT06564818)
  • 13 Aug 2024 Cybin conducted a type B initial breakthrough therapy meeting with the US FDA for CYB 003

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top